Johnson & Johnson (JNJ) announced results from the Phase 3 CEPHEUS study demonstrating a significant clinical improvement with ...

Janssen-Cilag International NV, a Johnson & Johnson company, announced three-year follow-up data from the Phase 3 CARTITUDE-4 study ...

JNJ files for voluntary bankruptcy for the third time. Pfizer withdraws sickle-cell drug drug Oxbryta from worldwide markets.

Johnson & Johnson and Legend Biotech's CAR-T cell therapy Carvykti reduced the risk of death by 45% compared to standard of ...

Legend Biotech said Friday its cancer drug, Carvykti, lowered the risk of death by 45% in a study of multiple myeloma patients.

Following the FDA's green light for a combo regimen of Sanofi’s Sarclisa in patients with newly diagnosed multiple myeloma ...

Ashraf Badros, MB, ChB, professor at the University of Maryland School of Medicine, director of the Multiple Myeloma Service, and vice chair of the Clinical Research Committee for the Program in ...

A new drug combination, talquetamab and teclistamab, shows promising results in treating patients with heavily pretreated ...

Multiple myeloma patients with COVID-19 have high rates of hospitalization, ICU admission, and death, according to researchers.